SCHEMBL6070568

SCHEMBL6070568

CN(C)/C=C1/CCc2c([nH]c3ccc([N+](=O)[O-])cc23)C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
LMNA P02545 3/20 0.56
TDP1 Q9NUW8 2/20 0.56
HTT P42858 1/20 0.56
NCOA1 Q15788 1/20 0.56
NCOA3 Q9Y6Q9 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
GFER P55789 1/20 0.48
RAB9A P51151 3/20 0.47
GSK3B P49841 8/20 0.45
CCNB2 O95067 7/20 0.45
CDK1 P06493 7/20 0.45
CCNB1 P14635 7/20 0.45
CDK5 Q00535 7/20 0.45
CDK5R1 Q15078 7/20 0.45
CCNB3 Q8WWL7 7/20 0.45
CDC7 O00311 1/20 0.45
PLK4 O00444 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6070573 1.00 MAPT (0.56) MAPTLMNATDP1HTTNCOA1
SCHEMBL6454820 0.86 MAPT (0.53) MAPTLMNATDP1HTTNCOA1
SCHEMBL13925707 0.81 MAPT (0.53) MAPTLMNAHTTSMN1; SMN2MEN1
SCHEMBL6071404 0.76 KDM4E (0.48) MAPTLMNASMN1; SMN2KMT2ARAB9A
SCHEMBL6071402 0.76 KDM4E (0.48) MAPTLMNASMN1; SMN2KMT2ARAB9A
SCHEMBL4162219 0.73 MAPT (0.69) MAPTLMNATDP1HTTNCOA1
SCHEMBL6239759 0.72 MAPT (1.00) MAPTLMNATDP1HTTNCOA1
SCHEMBL14366541 0.72 KDM4E (0.56) MAPTLMNAHTTSMN1; SMN2MEN1
SCHEMBL6997551 0.72 MAPT (0.60) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL5583246 0.72 KDM4E (0.56) MAPTLMNAHTTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed
EP-1599202-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-11-30 EP disclosed
WO-2004071507-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 MAPT 639/4885LMNA 2808/4885TDP1 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.